Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 17/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.70 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.68 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17425270 | 0.90 | HDAC6 (0.76) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL1365105 | 0.88 | HDAC1 (0.70) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL14095748 | 0.86 | HDAC6 (0.54) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL20879365 | 0.85 | HDAC1 (0.85) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL26159269 | 0.82 | HDAC1 (1.00) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL19278553 | 0.82 | HDAC1 (1.00) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL1367216 | 0.82 | HDAC1 (0.70) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL1368416 | 0.81 | HDAC6 (0.70) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL22855795 | 0.81 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL16474100 | 0.80 | HDAC6 (0.70) | HDAC6HDAC1HDAC8HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| EP-2343286-A1 | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2011-07-13 | — | — | EP | disclosed |
| EP-2343286-A1 | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2011-07-13 | — | — | EP | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | HDAC6 9/4885HDAC1 1/4885HDAC8 7/4885 |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC11 | HDAC6 11/4885HDAC1 1/4885HDAC8 9/4885 |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | HDAC6 11/4885HDAC1 3/4885HDAC8 8/4885 |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | HDAC6 9/4885HDAC1 1/4885HDAC8 8/4885 |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC11 | HDAC6 11/4885HDAC1 1/4885HDAC8 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.